<DOC>
	<DOCNO>NCT01703923</DOCNO>
	<brief_summary>The purpose study determine antitussive effect size dose response FP01 lozenges subject chronic cough demonstrate safety tolerability FP01 lozenges subject chronic cough .</brief_summary>
	<brief_title>An Exploratory Study FP01 Lozenges Subjects With Chronic Refractory Cough</brief_title>
	<detailed_description />
	<mesh_term>Cough</mesh_term>
	<criteria>Subject must sign Institutional Review Board approve inform consent agree complete require clinic visit Subjects must able read write English Subject must exceed cough severity threshold ( VAS ) screen visit ( Cough Severity VAS Score â‰¥ 35 mm ) Mean CSD frequency domain ( Only Questions 13 time screen ) score &gt; 3.0 Stable chest Xray Forced expiratory volume 1 ( FEV1 ) force vital capacity ( FVC ) &gt; 70 % predict measured use spirometry Body mass index ( BMI ) 18.5 38 Subjects must nonsmoker refrain use nicotine nicotine contain product least 6 month Female subject either postmenopausal ( amenorrhea least 12 consecutive month ) , surgically sterile , woman childbearing potential negative serum beta human chorionic gonadotropin pregnancy test prior enter study use agree use acceptable method contraception determine Investigator Recent significant change pulmonary status upper respiratory tract infection ( &lt; 4 week randomization ) Female subject pregnant , breast feeding sexually active without contraception . History chronic obstructive pulmonary disease ( COPD ) History asthma require significant change treatment within 2 week randomization . Subjects asthma eligible long subject treat oral steroid may enroll long new medication control asthma prescribe within two week study enrollment . History inhalational exposure ( chemical , smoke , water , etc . ) within 6 month randomization Chest Xray suggestive granulomatous disease , malignancy , pneumonia , acute pulmonary pleural process Current treatment angiotensin convert enzyme ( ACE ) inhibitor Recent myocardial infarction , history congestive cardiac failure Active , concomitant disease might limit ability subject participate study determine Investigator ( i.e. , diabetes mellitus , congestive heart failure , unstable angina , etc . ) Prior current renal disease ; calculate creatinine clearance &lt; 30 mL/min ( calculate CrCl &lt; 30 ) History Human Immunodeficiency Virus ( HIV ) current clinically significant liver disease Use opioids , neuromodulators ( eg. , gabapentin , pregabalin ) first generation antihistamine ( eg. , diphenhydramine , chlorpheniramine ) antidepressants treatment cough , study . Subjects take drug class chronic cough time screen may discontinue least 2 day prior randomization . Use NMDAreceptor antagonist ( e.g . dextromethorphan , ketamine , amantadine ) within 2 day randomization Use follow medication may interact memantine : quinidine , nicotine , neuroleptic chlorpromazine promethazine , amitriptyline , baclofen , warfarin hydrochlorothiazide Known hypersensitivity memantine hydrochloride Observation oral lesion ( ) abnormal find ( ) oral cavity examination do study screen Day 0 History oropharyngeal leukoplakia , carcinoma parotid dysfunction Subject clinically significant abnormal laboratory test result screen visit ( Subject may enrol exception , determine Principal Investigator consent Cerecor 's Medical Monitor . ) Subject clinically significant bleeding donate blood plasma within 30 day randomization Subject history alcohol drug abuse past 2 year Subject positive drug alcohol screen . Subjects receive benzodiazepine prescription , test positive benzodiazepine screen visit allow . Subjects disease condition ( medical surgical ) might compromise hematologic , cardiovascular , pulmonary , renal , gastrointestinal , central nervous system function ; condition might interfere absorption , distribution , metabolism , excretion study drug , would place subject increase risk , determine Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>